Biotechnology is the highest-risk, highest-reward segment in healthcare. Companies typically spend years and hundreds of millions of dollars in clinical trials before generating a single dollar of product revenue. Binary outcomes are the defining characteristic: a Phase III clinical trial success can double or triple a company's value; a failure can eliminate 70-90% of it overnight. This makes portfolio diversification and pipeline stage particularly important when assessing risk. Companies that have already commercialized at least one product have a fundamentally different risk profile from pre-revenue developers. The platform matters: gene editing, mRNA, cell therapy and other novel modalities offer the potential for multiple drugs from a single research approach, which significantly improves the long-term economics if the underlying biology proves out. For investors, biotech requires conviction in specific science and management teams, tolerance for binary stock-level risk and ideally a portfolio approach rather than concentrated single-company positions.
